Guardant Health Inc

Guardant Health, Inc. is a precision oncology company engaged in the treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. Its solutions include treatment selection, recurrence detection, and early detection. The company was founded by Helmy Eltoukhy, AmirAli H. Talasaz, and Michael Joseph Wiley in 2012 and is headquartered in Palo Alto, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Guardant Health reports robust Q1 earnings, eyes growth opportunities

Guardant Health's Q1 2023 earnings call showcased strong financial performance, advancements in screening technology, and a focus on operational efficiency. The company's revenue growth, successful Medicare reimbursement, and strategic guidance raise optimism for future growth. Challenges lie in managing expenses and commercial investments post-FDA approval.

Guardant Health reports robust Q2 results and eyes international expansion

Guardant Health's Q2 performance reflects strong revenue growth and test volume increase, with a focus on achieving cash flow breakeven.
The company's strengths lie in expanding payer coverage, advancing Shield blood tests, and seeing growth in the MRD market.
Challenges include legal expenses, low lung cancer screening rates, and managing cash burn, while opportunities exist in Japan market expansion and EMR integration.
Overall, Guardant Health is poised for growth with a strategic focus on innovation, market expansion, and financial sustainability.

Guardant Health reports strong Q3 performance, eyes international expansion

Guardant Health's Q3 2023 showcased robust revenue growth and strong test volume performance, particularly in Precision Oncology and Guardant360.
The company's focus on innovation, payer coverage breakthroughs, and international expansion presents significant growth opportunities.
While Shield V2 faces challenges in AA detection, progress on FDA approval and sales strategy post-approval are key areas of focus.
Overall, Guardant Health's strategic investments and product advancements position it well for continued growth and market leadership.

Guardant Health reports robust revenue growth and strategic advancements

Guardant Health's strong financial performance, focus on key strengths, and management of challenges position the company for continued growth
Opportunities in revenue growth, product upgrades, and market expansion present avenues for further success
Strategic initiatives in therapy selection, MRD, and screening underscore Guardant Health's commitment to innovation and market leadership

Guardant Health excels in Q2 2024 with FDA-approved Shield test

Guardant Health's Q2 2024 performance showcased strong revenue growth, driven by the success of the Shield blood test and Guardant360. While facing challenges in cash flow, the company remains optimistic about future opportunities in the diagnostic testing market.

Guardant Health reports robust Q3 earnings, eyes international expansion

Guardant Health's Q3 2024 earnings call highlighted strong revenue growth, exceeding expectations in key segments. The company raised its full-year revenue guidance and showcased improvements in free cash flow. Shield blood test and Reveal revenue are expected to drive future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Guardant Health, Inc. is a precision oncology company engaged in the treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. Its solutions include treatment selection, recurrence detection, and early detection. The company was founded by Helmy Eltoukhy, AmirAli H. Talasaz, and Michael Joseph Wiley in 2011 and is headquartered in Palo Alto, CA.

Guardant Health's share price has been volatile over the past year, but with strong clinical volume growth, the company presents an interesting investment opportunity. The company has diversified its revenue streams with new innovations such as the "Shield" blood test screener for colorectal cancer and the Guardant360 Response, which recently got approved for Medicare coverage. Despite negative net margins, the company is expected to lower operating expenses in 2023 and generate its first-ever positive EPS report by 2027.

Guardant Health: A Growth Company Expanding Its Product Line Quickly

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that it has been informed it will receive national reimbursement approval from the Japanese Ministry of Health, Labor and Welfare (MHLW), effective July 24, 2023, for its Guardant360® CDx liquid biopsy test for comprehensive genomic profiling (CGP) for patients with advanced or metastatic solid tumor cancers. This announcement follows the regulatory approval of the Guard.

Guardant Health announces reimbursement approval of Guardant360® CDx liquid biopsy test in Japan

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health will present 17 studies that highlight advances in precision oncology and cancer screening at the 2023 ASCO Annual Meeting in Chicago.

Guardant Health to present 17 scientific abstracts highlighting contribution of its blood tests and real-world data to advances in precision oncology and cancer screening at 2023 ASCO annual meeting

Guardant360® CDx is a comprehensive genomic profiling blood test that provides critical information to help inform personalized treatment decisions for patients with advanced solid cancers   The liquid biopsy test is also approved as a companion diagnostic for TAGRISSO® (osimertinib) in non-small cell lung cancer   This is the first blood test to be approved by Singapore's Health Sciences Authority for comprehensive genomic profiling for all solid tumors   SINGAPORE , May 29, 2023 /PRNewswire/ -- Guardant Health, Inc. (Nasdaq: GH) announced today that Singapore's Health Sciences Authority (HSA) has granted regulatory approval of Guardant360® CDx, a liquid biopsy test for tumor mutation profiling, also known as comprehensive genomic profiling (CGP), in patients with advanced solid cancers. The Guardant360 CDx test was also approved as a companion diagnostic to identify patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) alterations who may benefit from treatment with TAGRISSO® (osimertinib).

Guardant Health Receives Regulatory Approval from Singapore's Health Sciences Authority for Guardant360® CDx blood test for patients with advanced solid cancers

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences. William Blair 43rd Annual Growth Stock Conference in Chicago, IL Presentation on Tuesday, June 6th at 4:40 p.m. Central Time Goldman Sachs 44th Annual Global Healthcare Conference in Dana Point, CA Fireside Chat on Monday, June 12th at 4:00 p.m. Pacific Time Interested parties may access live and ar.

Guardant Health to Participate in Upcoming June Investor Conferences

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq:GH), a leading precision oncology company, today announced the pricing of an upsized underwritten public offering of 12,500,000 shares of its common stock at a public offering price of $28.00 per share, before deducting underwriting discounts and commissions. In addition, Guardant Health has granted the underwriters a 30-day option to purchase up to an additional 1,875,000 shares of common stock at the public offering price, less.

Guardant Health Announces Pricing of Upsized Public Offering of Common Stock

Guardant Health Inc. GH, +2.46% shares fell in the extended session Monday after the cancer testing company announced a secondary offering of its stock. Guardant shares rose as much as 8% after hours, following a 2.5% rise to close the regular session at $30.80.

Guardant Health stock falls after secondary offering announced

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq:GH), a leading precision oncology company, today announced that it has commenced an underwritten public offering of $250.0 million of its common stock. In addition, Guardant Health intends to grant the underwriters a 30-day option to purchase up to $37.5 million of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock in this offering will be sold by Guardant.

Guardant Health Announces Proposed Public Offering of Common Stock

Guardant said its Guardant360 liquid biopsy is receiving coverage from all four major U.S. health insurers. The company grew revenue by 34% in the first quarter, year over year, but had a net loss.

Why Shares of Guardant Health Jumped This Week

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health secures coverage from major US commercial health insurers for Guardant360® blood test for comprehensive genomic profiling.

Guardant Health Secures Coverage From Major US Commercial Health Insurers for Guardant360® Blood Test for Comprehensive Genomic Profiling

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today the publication of its inaugural Environmental, Social & Governance (ESG) Report, which provides information related to key ESG commitments that the company has laid out as part of its business strategy. “Our goal from day one has been to provide tests for patients at all stages of cancer so they can live longer and healthier lives,” said Helmy Eltoukhy, Guardant Hea.

Guardant Health Releases Inaugural ESG Report

Guardant added two women to its C-suite. The company reported positive data for its colon cancer screening product.

Why Guardant Health's Shares Climbed This Week

Guardant Health, Inc. (NASDAQ:GH ) Q1 2023 Earnings Conference Call May 9, 2023 4:30 PM ET Company Participants Alex Kleban - Vice President-Investor Relations Helmy Eltoukhy - Chairman & Co-Chief Executive Officer AmirAli Talasaz - Co-Chief Executive Officer Mike Bell - Chief Financial Officer Craig Eagle - Chief Medical Officer Conference Call Participants Dan Arias - Stifel Puneet Souda - SVB Securities Jack Meehan - Nephron Research Kyle Mikson - Canaccord Julia Qin - JPMorgan Dave Delahunt - Golden Sachs. Mark Massaro - BTIG Tejas Savant - Morgan Stanley Operator Hello, and welcome to the Guardant Health First Quarter 2023 Financial Results Call.

Guardant Health, Inc. (GH) Q1 2023 Earnings Call Transcript

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics, today reported financial results for the quarter ended March 31, 2023. First Quarter 2023 Financial Highlights Revenue of $128.7 million for the first quarter of 2023, an increase of 34% over the first quarter of 2022 Reported 39,100 tests to clinical customers and 6,15.

Guardant Health Reports First Quarter 2023 Financial Results

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today presented additional data from the ECLIPSE study at 2023 Digestive Disease Week (DDW) titled, “Clinical Validation of a Cell-Free DNA Blood-Based Test for Colorectal Cancer in an Average Risk Population” (Abstract #913e) showcasing the performance of its blood-based technology to accurately detect early-stage colorectal cancer (CRC). The ECLIPSE (Evaluation of ctDNA LUNAR Assay In.

Guardant Health presents additional information from ECLIPSE study at 2023 Digestive Disease Week on the performance of Shield™ blood test

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the expansion of its leadership team with the addition of Ines Dahne-Steuber as chief operating officer and the promotion of Darya Chudova to chief technology officer. “At Guardant, we have built one of the most transformative platforms in diagnostics and we think extensively about how we get work done more efficiently, from development through delivery, to fulfill our p.

Guardant Health Announces Additions to Leadership Team

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report additional data from its pivotal ECLIPSE study at Digestive Disease Week (DDW) on Tuesday, May 9, 2023. The company will host a webcast and conference call with primary investigators of the study and other cancer screening experts beginning at 11:00 a.m. ET / 8:00 a.m. PT. Live audio of the webcast will be available on the “Investors” section of the compan.

Guardant Health Announces ECLIPSE Study Update Call on May 9, 2023

Guardant Health (GH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Guardant Health (GH) Expected to Beat Earnings Estimates: Should You Buy?

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the upcoming BofA Securities 2023 Healthcare Conference in Las Vegas, Nevada. Guardant Health's management is scheduled to present a fireside chat on Wednesday, May 10th at 2:20 p.m. Pacific Time / 5:20 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the co.

Guardant Health to Participate in the BofA Securities 2023 Healthcare Conference

Guardant Health (GH) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Down -6.66% in 4 Weeks, Here's Why You Should You Buy the Dip in Guardant Health (GH)

PALO ALTO, Calif., & SAN FRANCISCO--(BUSINESS WIRE)--Guardant Health and Parker ICI will study the correlation between molecular cancer biomarkers and patient response to immunotherapy treatment.

Guardant Health and Parker Institute for Cancer Immunotherapy (PICI) launch research collaboration to study connection between cancer biomarkers and immunotherapy treatment response

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, is pleased to announce that it will present data from two studies highlighting the performance of its blood-based screening technology to detect early-stage colorectal cancer (CRC), including the acceptance of the ECLIPSE study as a late-breaking abstract, at Digestive Disease Week (DDW) taking place in Chicago, Illinois on May 6-9, 2023.

Guardant Health announces new data to be presented at 2023 Digestive Disease Week showcasing the potential of its blood-based technology to detect colorectal cancer

Shares of liquid biopsy genetic profiling test developer Guardant Health, Inc. have cratered 85% since achieving their all-time high of $181.07 in February 2021. Slowing top line growth, a very long timeline to profitability that includes a significant cash burn, and disappointing (versus expectations) data regarding its Shield colorectal test are to blame.

Guardant Health: On Hold For Now

The mean of analysts' price targets for Guardant Health (GH) points to a 123.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Predict a 123.55% Upside in Guardant Health (GH): Here's What You Should Know

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the first quarter of 2023 after market close on Tuesday, May 9, 2023. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the “Investors” section of the company website at: www.guardanthealth.com.

News for Guardant Health Inc Stock (GH)